Zeenat Safdar1, Emilio Tamez1, Adaani Frost1, Danielle Guffey2, Charles G Minard2, Mark L Entman3. 1. Division of Pulmonary, Critical Care, and Sleep Medicine, Baylor College of Medicine, USA. 2. Dan L Duncan Institute for Clinical and Translational Research, Baylor College of Medicine, USA. 3. Division of Cardiology, Baylor College of Medicine, USA.
Abstract
OBJECTIVES: The goal of this study was to investigate the association between collagen metabolism biomarkers and health related quality of life (HRQoL) in PAH patients. METHODS: We prospectively enrolled 68 stable idiopathic, anorexigen-associated, and hereditary PAH subjects and 37 healthy controls. Serum samples were analyzed for N-terminal propeptide of type III procollagen (PIIINP), c-terminal telopeptide of collagen type I (CITP), matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of metalloproteinase 1 (TIMP-1). The Minnesota Living with Heart Failure (MLWHF), Euro QoL-5D (EQ-5D), Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) and Short Form (SF-36) general health survey were administered at the time of blood draw. General linear models, as well as logistic regression models were used to assess associations between variables. RESULTS: CITP, PIIINP, MMP9, and TIMP1 levels, and all HRQoL domains were significantly different between controls and PAH patients (p<0.001 for each). Interestingly, PIIINP levels were significantly associated with MLWHF physical (coef=1.63, and p=0.02), SF-36 physical (coef=-2.93, p=0.004), and EQ-5D aggregate (coef=0.34, p=0.001) scores. Several of the CAMPHOR scores strongly linearly associated with PIIINP. The odds of obtaining a walk distance ≥330 meters decrease by 38% per unit increase in PIIINP (OR=0.62; 95% CI=0.43, 0.90) and a PIIINP cutoff of 5.53 μg/L provided 81% sensitivity and 82% specificity. CONCLUSIONS: PIIINP is a good predictor of disease severity, and is strongly related to HRQoL scores in PAH patients. These relationships suggest PIIINP as a promising tool for PAH clinicians to determine or confirm the level of disease severity.
OBJECTIVES: The goal of this study was to investigate the association between collagen metabolism biomarkers and health related quality of life (HRQoL) in PAHpatients. METHODS: We prospectively enrolled 68 stable idiopathic, anorexigen-associated, and hereditary PAH subjects and 37 healthy controls. Serum samples were analyzed for N-terminal propeptide of type III procollagen (PIIINP), c-terminal telopeptide of collagen type I (CITP), matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of metalloproteinase 1 (TIMP-1). The Minnesota Living with Heart Failure (MLWHF), Euro QoL-5D (EQ-5D), Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) and Short Form (SF-36) general health survey were administered at the time of blood draw. General linear models, as well as logistic regression models were used to assess associations between variables. RESULTS:CITP, PIIINP, MMP9, and TIMP1 levels, and all HRQoL domains were significantly different between controls and PAHpatients (p<0.001 for each). Interestingly, PIIINP levels were significantly associated with MLWHF physical (coef=1.63, and p=0.02), SF-36 physical (coef=-2.93, p=0.004), and EQ-5D aggregate (coef=0.34, p=0.001) scores. Several of the CAMPHOR scores strongly linearly associated with PIIINP. The odds of obtaining a walk distance ≥330 meters decrease by 38% per unit increase in PIIINP (OR=0.62; 95% CI=0.43, 0.90) and a PIIINP cutoff of 5.53 μg/L provided 81% sensitivity and 82% specificity. CONCLUSIONS: PIIINP is a good predictor of disease severity, and is strongly related to HRQoL scores in PAHpatients. These relationships suggest PIIINP as a promising tool for PAH clinicians to determine or confirm the level of disease severity.
Authors: Sebastian Stintzing; Peter Heuschmann; Letterio Barbera; Matthias Ocker; Andreas Jung; Thomas Kirchner; Daniel Neureiter Journal: Ann Vasc Surg Date: 2005-05 Impact factor: 1.466
Authors: Harrison W Farber; Dave P Miller; Michael D McGoon; Adaani E Frost; Wade W Benton; Raymond L Benza Journal: J Heart Lung Transplant Date: 2014-08-28 Impact factor: 10.247
Authors: Nishan Guha; Ioulietta Erotokritou-Mulligan; Christiaan Bartlett; David A Cowan; E Eryl Bassett; Michael Stow; Peter H Sönksen; Richard I G Holt Journal: Drug Test Anal Date: 2012-04-17 Impact factor: 3.345
Authors: Andriana Nikolova; Klemens Ablasser; Moritz C Wyler von Ballmoos; Dimitrios Poutias; Elisabeth Kaza; Francis X McGowan; Marsha A Moses; Pedro J Del Nido; Ingeborg Friehs Journal: Ann Thorac Surg Date: 2012-07-12 Impact factor: 4.330
Authors: Marcus Franz; Katja Grün; Stefan Betge; Ilonka Rohm; Bernadin Ndongson-Dongmo; Reinhard Bauer; P Christian Schulze; Michael Lichtenauer; Iver Petersen; Dario Neri; Alexander Berndt; Christian Jung Journal: Oncotarget Date: 2016-12-06